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REGULAR ARTICLE
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Key Points
•Combining
phosphatidylinositol-3-
kinase d inhibition with
rituximab, bendamus-
tine, or both is feasible
and active in relapsed
iNHL.
• The safety of novel
combinations should
be proven in phase 3
trials before adoption in
clinical practice.
Idelalisib, a ﬁrst-in-class oral inhibitor of phosphatidylinositol-3-kinase d, has shown
considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin
lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combination with
immunotherapy, chemotherapy, or both, 79 patients with relapsed/refractory iNHL were
enrolled based on investigator preference in 3 treatment groups. Patients received
continuous idelalisib in combination with (1) rituximab (IR; 375 mg/m2 weekly 3 8 doses),
(2) bendamustine (IB; 90 mg/m2 per day 3 2, for 6 cycles), or (3) both bendamustine and
rituximab at aforementioned doses (IBR; monthly 3 6 cycles). Patients had a median age
of 61 years, a median of 3 prior therapies, and 46% had refractory disease. The overall
response rate was 75% (22% complete response) for IR, 88% (36%) for IB, and 79% (43%) for
IBR. The median progression-free survival was 37.1 months overall: 29.7 months for IR,
32.8 for IB, and 37.1 months for IBR. The median duration of response was 28.6 months in
the IR group and has not been reached in the IB and IBR groups. The most common grade
$3 adverse events and laboratory abnormalities were neutropenia (41%), pneumonia (19%),
transaminase elevations (16%), diarrhea/colitis (15%), and rash (9%). The safety and eﬃcacy
reﬂected in these early data, however, stand in contrast with later observations of signiﬁcant
toxicity in subsequent phase 3 trials in frontline chronic lymphocytic leukemia and less
heavily pretreated iNHL patients. Our ﬁndings highlight the limitations of phase 1 trial data
in the assessment of new regimens. This trial was registered at www.clinicaltrials.gov
as #NCT01088048 (an extension study was registered at www.clinicaltrials.gov as
#NCT01090414).
Introduction
In 2015, approximately 20 000 people in the United States were diagnosed with indolent non-Hodgkin
lymphomas (iNHL), and 7000 died of the disease.1,2 Treating recurrent iNHL continues to be
challenging. Current therapies commonly include anti–cluster of differentiation 20 antibodies, such as
rituximab3 (US approval in 1997) and the alkylator bendamustine4 (US approval in 2008), which have
demonstrated activity and tolerability in combination with rituximab.5 Although initially effective for iNHL,
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standard chemotherapy and immunotherapy generally demonstrate
decreasing efficacy with repeated administration.6-9 Thus, there is an
unmet need for new treatments with different mechanisms of action,
either as monotherapy or in combination with standard-of-care
regimens, for patients with relapsed/refractory iNHL. With significant
advances in the development of nonchemotherapeutic agents,
“chemotherapy-free” regimens for iNHL are now an approach
desired by many patients. However, there is also a need for more
efficacious chemotherapy-containing regimens. The 20% of patients
with follicular lymphoma (FL) treated with rituximab, cyclophospha-
mide, doxorubicin hydrochloride, vincristine sulfate, and prednisone
who progress within 2 years of diagnosis have a substantially
increased risk of death within 5 years after diagnosis.10
Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that exists in 4
different isoforms: a, b, g, and d. In B lymphocytes, the d isoform
(PI3Kd) plays a central role in normal B-cell development and
function, transducing signals from the B-cell receptor and from
receptors for various cytokines, chemokines, and integrins.11,12
Further, PI3Kd signaling pathways are commonly hyperactive in
B-cell malignancies.13,14 Idelalisib is a potent, small-molecule inhibitor
of PI3K that is selective for the d isoform.15 In lymphoid cell lines and
primary patient samples, idelalisib inhibits PI3Kd/AKT signaling and
promotes apoptosis.16 A phase 1 trial demonstrated significant
antitumor activity of idelalisib monotherapy in patients with relapsed
iNHL with an overall response rate (ORR) of 48%, a median
progression-free survival (PFS) of 7.6 months, and a median duration
of response (DOR) of 18.5 months.17 A phase 2 study in patients
with iNHL refractory to rituximab and an alkylating agent (n 5 125)
showed significant antitumor activity, with an ORR of 57%, including
6% complete responses (CRs), a median PFS of 11 months, and a
median DOR of 12.5 months.18 Based on these data, the Food and
Drug Administration granted idelalisib accelerated approval for
treatment of patients with relapsed FL and small lymphocytic
lymphoma (SLL) who had received at least 2 prior systemic therapies.
Based on single-agent activity in indolent lymphoma, we conducted
a phase 1 trial evaluating idelalisib in combination with commonly
used antilymphoma standard-of-care agents. Our objectives were to
characterize the drug’s safety and clinical activity in combination with
rituximab immunotherapy, bendamustine chemotherapy, or combined
chemoimmunotherapy and to identify regimens to be tested in phase
3 studies.
Patients and methods
The present study describes the iNHL subgroup of a larger open-label study
of idelalisib in patients with relapsed or refractory iNHL or chronic
lymphocytic leukemia (CLL). The primary trial evaluated patients through
48 weeks of idelalisib treatment, followed by an extension study offering
continued single-agent idelalisib therapy for patients who derived clinical
benefit. The study protocol was approved by institutional review boards
across the 11 participating study centers. All patients provided written
informed consent before enrollment. These studies were conducted under
a US Investigational New Drug Application in accordance with the
International Conference on Harmonization guidelines for Good Clinical
Practice and the original principles embodied in the Declaration of Helsinki.
All authors had full access to study data and were involved in data
interpretation, manuscript preparation, revision, and final approval.
Inclusion criteria
Previously treated patients with a confirmed diagnosis of FL (grades 1, 2, and
3a), SLL, or marginal zone lymphoma (MZL) were eligible.19 Patients must
have been previously treated and relapsed or had refractory disease (defined
as not responding to a standard regimen or progressing within 6 months of
completing a standard regimen). Measurable disease consisting of $1 lesion
of .2 cm in a single dimension by computed tomography (CT) scan was
required. Patients were $18 years of age and had a World Health
Organization performance status of #2.
Exclusion criteria
Key exclusion criteria included known active central nervous system lymphoma,
active serious infection requiring systemic therapy, or prior allogeneic stem cell
transplantation. Adequate bone marrow function was required and defined
as no worse than mild neutropenia (absolute neutrophil count ,1000/mL)
or thrombocytopenia (,75 000/mL). Other reasons for exclusion were
serum creatinine $2.0 mg/dL, serum bilirubin $2.0 mg/dL, serum transam-
inases $2 times the upper limit of normal (ULN), Child-Pugh class B or C
hepatic impairment, serologic evidence of HIV, or active hepatitis B or hepatitis
C. Female patients were excluded if they were pregnant or nursing.
Study design and treatments
The study was an open-label, unstratified, and nonrandomized phase 1 trial.
Patients were treated in 1 of 3 cohorts based on investigator’s choice and
received continuous oral therapy with idelalisib.4 The treatment groups
received either rituximab (IV infusion of 375 mg/m2 weekly for 8 doses),
bendamustine (30-minute IV infusion of 90 mg/m2 on days 1 and 2), or the
combination of bendamustine and rituximab (bendamustine at 90 mg/m2 on
days 1 and 2, then rituximab at 375 mg/m2 on day 1), and all groups received
twice-daily idelalisib. Idelalisib was provided as 100- or 150-mg tablets, with
75- and 50-mg tablets available for dose reductions. The idelalisib dose
was based on safety, efficacy, and pharmacokinetic data from phase 1
monotherapy studies in iNHL and CLL.17,20
The 3 main treatment groups are not comparable because they were not
stratified or balanced in this trial. Patients in the first 2 cohorts were enrolled
to the continuous idelalisib in combination with rituximab (IR; n 5 8) and
continuous idelalisib in combination with bendamustine (IB) groups (n 5 8)
and received idelalisib at 100 mg orally twice daily. After adequate safety
was established, all subsequent patients in the following cohorts received
150 mg of idelalisib orally twice daily. In addition, a group was assigned to
the combination of bendamustine, rituximab, and idelalisib (IBR; n 5 14). In
an attempt to decrease the incidence of transaminase elevations, subgroups
with delayed initiation of idelalisib (28-day delay) were assessed, either with
rituximab or with bendamustine (n 5 12 each). Unless disease progression
Table 1. Disposition of patients in the 7 subgroup-specific cohorts of
the primary and extension studies
Enrolled in
primary study
(n 5 79)
Enrolled in
extension study
(n 5 35) (%)
Ongoing
(n 5 17) (%)
Idela 1 R 32 14 (44) 6 (19)
Idela 100 mg 8 3 (38) 3 (38)
Idela 150 mg 12 8 (67) 1 (8)
Delayed Idela 150 mg 12 3 (25) 2 (17)
Idela 1 B 33 15 (45) 8 (24)
Idela 100 mg 8 1 (13) 1 (13)
Idela 150 mg 13 9 (69) 6 (46)
Delayed Idela 150 mg 12 5 (42) 1 (8)
Idela 1 BR
Idela 150 mg 14 6 (43) 3 (21)
B, bendamustine; Idela, idelalisib; R, rituximab.
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Table 2. Patient characteristics and disposition (primary study, unless otherwise indicated)
Idela 1 R (n 5 32) Idela 1 B (n 5 33) Idela 1 BR (n 5 14) All patients (n 5 79)
Age, median (range), y 65 (40-84) 59 (37-80) 56 (48-76) 61 (37-84)
Sex, male, n (%) 22 (69) 22 (67) 8 (57) 52 (66)
Disease subtype, n (%)
FL 23 (72) 25 (76) 11 (79) 59 (75)
SLL 7 (22) 6 (18) 2 (14) 15 (19)
MZL 2 (6) 2 (6) 1 (7) 5 (6)
Prognostic factors, n (%)
Performance status $1 12 (37) 17 (52) 4 (29) 33 (41)
Stage IV 20 (63) 17 (52) 8 (57) 46 (57)
Bulky adenopathy (.5 cm) 16 (50) 18 (54) 5 (36) 39 (48)
Bone marrow involvement 14 (44) 14 (42) 4 (29) 32 (41)
b2 microglobulin (.ULN) 18 (56) 22 (67) 7 (50) 47 (59)
LDH (.ULN) 9 (28) 9 (27) 4 (29) 22 (28)
FLIPI score (FL patients)
0/1 2 (9) 5 (20) 4 (36) 11 (19)
2 10 (43) 11 (44) 2 (18) 23 (39)
$3 8 (35) 7 (28) 5 (46) 20 (34)
Missing 3 (13) 2 (8) 0 5 (8)
Prior therapies, median, n (range) 3 (1-9) 3 (1-10) 3 (1-8) 3 (1-11)
Rituximab-containing regimen, % 93 100 100 97
Rituximab monotherapy as only prior treatment, % 0 6 14 5
Rituximab monotherapy as last prior treatment, % 16 39 29 28
Alkylating agent, % 90 82 86 86
Anthracycline, % 50 49 57 51
Bendamustine, % 40 21 29 32
Purine analog, % 20 33 14 25
Platinum agent, % 16 18 7 15
ASCT, % 9 6 7 8
Disease status, n (%)
Relapsed 19 (59) 19 (58) 5 (36) 43 (56)
Refractory* 13 (41) 14 (42) 9 (64) 36 (46)
Idela dose received, n (%)
100 mg twice daily 8 (25) 8 (24) 0 16 (20)
150 mg twice daily 24 (75) 25 (76) 14 (100) 64 (81)
Duration of Idela therapy, median (range), mo
Primary 1 extension study 10.0 (0.5-33) 9.9 (0.6-32.3) 11.4 (0.9-25.3) 10.1 (0.5-33)
Treatment disposition, n (%)
Received study drug 32 (100) 33 (100) 14 (100) 79 (100)
Completed cycle 2 32 (100) 32 (97) 11 (79) 75 (95)
Discontinued from primary study 16 (50) 18 (54) 8 (57) 42 (53)
Enrolled in extension study 14 (44) 15 (45) 6 (43) 35 (44)
Discontinued from extension study 8 (57) 7 (47) 3 (50) 18 (51)
Reasons for early discontinuation, primary
study, n (%)
AE 6 (19) 6 (18) 4 (29) 16 (20)
Disease progression 4 (12) 4 (12) 1 (7) 9 (11)
Patient/investigator request 1 (3) 4 (12) 1 (7) 6 (8)
ASCT, allogeneic stem cell transplantation; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.
*Refractory is defined as a lack of response or progression within 6 mo of completion of last therapy.
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or intolerable toxicity occurred, patients could continue idelalisib through 48
weeks on the primary study (12 28-day cycles) and indefinitely on the
extension study. The disposition of all treatment groups is summarized in
Table 1.
Pretreatment evaluation
Screening assessments included documentation of iNHL diagnosis, staging
(Ann Arbor system), prognostic factors (Follicular Lymphoma International
Prognostic Index), B symptoms, World Health Organization performance
status, physical examination, clinical laboratory tests, vital signs, 12-lead
electrocardiogram, and disease status (including a CT scan and bone marrow
biopsy if not already performed within 6 weeks before study initiation). At
baseline, the following procedures were performed before study drug dosing:
recording of adverse events (AEs); vital signs, electrocardiogram; and clinical
laboratory tests, including serum immunoglobulin A (IgA), IgE, IgG, and IgM;
and serum b2-microglobulin.
Safety assessments
All AEs were evaluated, and complete blood counts and standard serum
chemistry tests were collected every 2 weeks for 12 weeks, then every
4 weeks for 12 weeks, and thereafter every 12 weeks. Serum immunoglobulins
were measured at 12-week intervals through week 48. AEs were coded using
the Medical Dictionary for Regulatory Activities (MedDRA), and the severity
of AEs and laboratory abnormalities were graded using the Common
Terminology Criteria for Adverse Events, version 4.02.21 Only serious AEs
(SAEs) and grade $3 AEs were collected during the extension phase of
the study.
Efficacy assessments
Patients were evaluated for disease response or progression every 8 weeks
(weeks 8, 16, and 24) and then at 12-week intervals (week 36 onward). The
ORR was derived from the best response measured from start of treatment
until disease progression or early discontinuation. Nodal responses were
calculated from the sum of the product of the greatest perpendicular diameters
(SPD). CR, partial response (PR), stable disease (SD), and progressive
disease (PD) were assessed using standard criteria.22 Bone marrow biopsies
were performed as needed to confirm a CR and were required at week 24.
Patients who hadPD at any point stopped study drug treatment and discontinued
the study.
Statistical analysis
Because this was a phase 1 study with the primary objective to assess
safety, the sample size was not based on power calculations. The sample
size of approximately 6 in cohorts 1a and 1b was based on the standard 313
design with a target observed dose-limiting toxicity threshold of 33%. The
sample size of approximately 12 for the next cohorts was considered adequate
for an initial assessment of safety and tolerability for subsequent evaluations.
Unless otherwise noted, data from the primary and extension studies were
analyzed together. All safety and efficacy analyses were based on the intent-
to-treat analysis set, which included all patients who received at least 1 dose
of study drug (idelalisib or combination therapy). The ORR was presented
with a 2-sided 95% confidence interval (CI) using the exact method. PFS,
DOR, and overall survival were summarized using the Kaplan-Meier (KM)
method. Time to response (TTR) and DOR were analyzed in responding
patients.
Results
Patient characteristics
Beginning in March 2010, 79 patients with iNHL were enrolled
(Table 2). The primary 48-week study (Study 101-07) was completed
in January 2013, and the extension study (Study 101-99) is ongo-
ing; the present analysis is based on data up to October 2014.
Demographics show that most (65.8%) patients were male and
the median age was 61 years (range, 37-84). Lymphoma subtypes
included FL (59 patients, 74.7%), SLL (15 patients, 19.0%), andMZL
(5 patients, 6.3%). At baseline, patients frequently demonstrated
elevated b2 microglobulin (59%), stage IV disease (57%), bulky
adenopathy (.5 cm; 48%), anemia (hemoglobin ,12 g/dL; 41%),
and elevated lactate dehydrogenase (28%) in the context of a median
of 3 prior therapies (range, 1-11). Most patients had received a
rituximab-containing regimen, an alkylating agent, or an anthracycline
(Table 2). Zero, 6%, and 14% of patients in the IR, IB, and IBR
cohorts, respectively, received rituximab monotherapy as their only
prior therapy. Approximately 46% of patients were refractory to their
last prestudy therapy, and 58% of patients were refractory to
rituximab (defined as lack of response or progression ,6 months
since completion of last regimen).
Table 2. (continued)
Idela 1 R (n 5 32) Idela 1 B (n 5 33) Idela 1 BR (n 5 14) All patients (n 5 79)
Withdrew consent 1 (3) 1 (3) 2 (14) 4 (5)
Worsening disease/symptoms 2 (6) 1 (3) 0 3 (4)
Death 1 (3) 1 (3) 0 2 (3)
SCT 1 (3) 0 0 1 (1)
Reasons for discontinuation, extension study, n (%)
Disease progression 5 (36) 2 (13) 1 (17) 8 (23)
AE 2 (14) 1 (7) 2 (33) 5 (14)
Death 0 2 (13) 0 2 (6)
Investigator request 0 1 (7) 0 1 (3)
SCT 0 1 (7) 0 1 (3)
Withdrew consent 1 (7) 0 0 1 (3)
ASCT, allogeneic stem cell transplantation; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.
*Refractory is defined as a lack of response or progression within 6 mo of completion of last therapy.
13 DECEMBER 2016 x VOLUME 1, NUMBER 2 IDELALISIB COMBINATION THERAPY FOR iNHL 125
Patient disposition
The 3main treatment groups contained a total of 7 subgroups as listed
in Table 1: rituximab1100mg idelalisib, rituximab1 idelalisib 150mg,
rituximab 1 150 mg delayed idelalisib, bendamustine 1 100 mg
idelalisib, bendamustine1 150mg idelalisib, bendamustine1 150mg
delayed idelalisib, and bendamustine/rituximab1 150 mg idelalisib. All
regimens were administered twice daily. Analysis of safety and efficacy
revealed no significant differences within the 3 IR subgroups and the 3
IB subgroups (see the supplemental Data); these subgroups were
thus consolidated in subsequent analyses.
All patients in the intent-to-treat analysis set (N 5 79) received
idelalisib. The median duration of exposure for all patients in the study
was 10.1 months (range, 0.5-32.71). Specifics of disposition for all
patients in the 3 main treatment groups are listed in Table 2. Thirty-
seven patients (46.8%) completed the primary study and received
at least 48 weeks of treatment. Forty-two patients discontinued
the primary study. Reasons for discontinuation were AEs (16
patients, 20%), PD (9 patients, 11%), patient/investigator request
(n 5 6), withdrawal of consent (n 5 4), worsening disease/
symptoms not meeting criteria for progression (n 5 3), death
(n5 2), and stem cell transplantation (SCT; n5 1). Two additional
patients completed the primary study but did not enroll in the
extension study because of cholecystitis and investigator de-
cision, respectively.
In the extension study, 35 patients continued with idelalisib treatment.
Seventeen patients were on study at the data cutoff. Eighteen
patients discontinued treatment in the extension study. The most
common reasons were PD (8 patients), AEs (5 patients), death
(2 patients), investigator request, SCT, and withdrawal of consent
(1 patient each).
Safety profile
The incidences of treatment-emergent AEs (TEAEs) and laboratory
abnormalities (regardless of attribution) are listed in Table 3. The
table lists AEs of any grade ($15% incidence), as well as associated
rates of grade $3 AEs, by treatment cohort and total group. The
most frequently reported nonlaboratory TEAEs of any grade were
pyrexia (54%), nausea (44%), fatigue (43%), rash (38%), diarrhea or
colitis (37%), cough (35%), insomnia (23%), pneumonia (22%), and
upper respiratory infection (20%).
The most frequently reported (.1 patient) grade $3 TEAEs were
pneumonia (19%), diarrhea/colitis (15%), rash (9%), fatigue (4%),
and pyrexia (2%). The most common grade $3 laboratory ab-
normalities included lymphocytopenia (62%), neutropenia (41%),
increased alanine aminotransferase (ALT; 16%), anemia (10%), and
thrombocytopenia (8%). Grade $3 cytopenias were more common
in the 2 bendamustine-containing cohorts. Grade$ 3 increased ALT
occurred in 5/32 (16%) patients in the IR group and 8/33 (24%) in
the IB group; no cases occurred in the IBR group.
AEs leading to discontinuation in the primary study included
increased aspartate aminotransferase (AST/ALT; n 5 3), rash
(n 5 3), diarrhea/colitis (n 5 3), as well as anemia, myelodys-
plastic syndrome, thrombocytopenia, febrile neutropenia, fevers/
weight loss, suicidal ideation, and vomiting (n 5 1 each). AEs
leading to discontinuation in the extension study (n 5 5) included
2 patients with diarrhea/colitis and 1 patient each with cardiac
arrest, esophageal cancer, and rash.
SAEs occurring in more than 1 patient are listed in Table 4. These
included pneumonia (16%), pyrexia (14%), diarrhea/colitis (9%),
rash (8%), febrile neutropenia (6%), sepsis (6%), acute renal failure
(4%), and atrial fibrillation, cardiac arrest, herpes zoster infection,
pneumonitis, and vomiting (3% each).
Two patients (3%) experienced a TEAE leading to death during the
primary study. The causes, as determined by the investigator, were
cardiac arrest (in the IR cohort) and sepsis (in the IB cohort). One
additional patient (from the IB cohort) died of a lung infection 66
days after treatment ended. Two patients died during the extension
study, 1 from a cerebrovascular accident and the other from sepsis,
both in the IB cohort. All AEs leading to death were reported as
unrelated to study drugs.
Grade $3 diarrhea or colitis was seen in 12 patients (15%), equally
distributed across the 3 treatment groups. As in prior studies, symptoms
typically consisted of painless, watery diarrhea, without blood or mucus,
and had amedian onset of 9months (range, 2-37months). Events were
managed by supportive care measures as previously reported.23 Six
patients were able to continue on study after drug interruption and
improvement or resolution of the diarrhea/colitis (1 of the 6 received IV
hydrocortisone). Two patients permanently discontinued treatment
(1 treated with oral prednisolone and 1 treated with oral mesalazine)
and 4 patients had previously discontinued idelalisib before the onset of
the diarrhea/colitis and were not rechallenged.
Any-grade rash occurred in 38% of patients, including 7/79 (9%)
grade$3 rash: 2/32 (6%) patients in the IR cohort, 2/33 (6%) in the
IB cohort, and 3/14 (21%) in the IBR cohort. Four patients with grade
$3 rash also had other AEs, including elevated ALT (n 5 1),
neutropenia (n 5 1), pyrexia (n 5 1), bronchitis (n 5 1), dehydration
(n5 1), supraventricular tachycardia (n5 1), and atrial fibrillation (n5
1). Four patients were rechallenged with idelalisib; 1 had a
recurrence of grade 3 rash, and 3 patients were able to tolerate
further idelalisib treatment.
For patients with suspected pneumonitis (eg, onset of cough,
dyspnea, hypoxia, diffuse interstitial pattern or ground-glass opacities
on chest imaging without obvious infectious etiology), idelalisib was
interrupted. Pneumonitis occurred in 2 patients (at 4 and 5 months) in
the IB treatment group; both cases were managed with drug
interruption and antibiotic treatment (no steroids), and 1 patient
was rechallenged without recurrence.
Efficacy
Of the 79 patients enrolled, 64 had a response, for an ORR of 81%
(95% CI, 70.6-89.0) (Figure 1A). CRs were demonstrated in 25
patients (32%) and PRs in 39 patients (49%). In addition, 7 patients
had SD (9%) and 4 patients had PD (5%) as best on-study response.
Four patients were nonevaluable because they did not have follow-up
CT scans.
The groups are not comparable because they were not designed
to be stratified or balanced in this trial. However, by treatment group,
the ORR was 75% (95% CI, 57-89) for the IR group (n 5 24/32),
88% (95% CI, 72-97) for the IB group (n5 29/33), and 79% (95%
CI, 49-95) for the IBR group (n 5 11/14) (Figure 1A). The CR rates
were 22% (n 5 7/32), 36% (n 5 12/33), and 43% (n 5 6/14),
respectively. SD was noted in 4/32 patients (13%), 3/33 patients
(9%), and 0/14 patients in the 3 groups, respectively. Nonevaluable
patients included 2/32 in the IR group (needed radiotherapy,
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elevated liver function test) and 2/14 in the IBR group (intractable
nausea/vomiting, withdrew consent). For patients with FL, the ORR
(CR rate) was 74% (26%), 88% (44%), and 82% (45%) for the IR,
IB, and IBR cohorts, respectively.
A waterfall plot of the best overall nodal response for all iNHL
subtypes revealed that 73/75 (97%) of evaluable patients had some
reduction in disease burden during treatment (Figure 1B). One
patient progressed through therapy in the IB group. Responding
patients experienced rapid reduction in lymphadenopathy; median
TTR was 1.9 months (range, 1.0-16.6) (Figure 2A). Approximately
75% of responding patients demonstrated a response at their first
CT scan at 8 weeks. However, some responses occurred later, and
2 patients converted from SD to PR in the extension study (1 each
in the IR and IBR groups), both occurring at 16.6 months. The
proportion of patients who responded and enrolled in the extension
study was 42% in the IB group, 38% in the IR group, and 36% in the
IBR group. Median time to CR was 8.2 months (range, 1.8-31.7
months). In addition, 3 patients converted from PR to CR in the
extension study (2 in the IR group and 1 in the IB group). Although
most responses occurred early, typically within weeks, some clinical
responses occurred late, and some responses may have improved
over time. The TTR by treatment group revealed minimal differences
in response kinetics between the 3 groups (Figure 2B).
Median DOR has not yet been reached; frequency of continued
response was 66% at 24 months and 55% at 36 months (Figure 2C).
Median DOR has been reached for the IR group (28.6 months), but has
not yet been reached for the IB and IBR groups (Figure 2D). Themedian
PFS for the overall population was 37.1 months (Figure 2E). Themedian
PFS was 29.7, 32.8, and 37.1 months for the IR, IB, and IBR groups,
respectively (Figure 2F). Median overall survival was not reached during
the observation period (data not shown), and the KM estimate of the
proportion of surviving patients at 24 months was 91.5%.
Discussion
This noncomparative, nonrandomized phase 1 study constitutes
the first clinical assessment of IR and/or bendamustine for the
treatment of iNHL. No new treatment-related toxicities were identified.
The observed AE profile was consistent with previous trials of idelalisib,
immunotherapy, or chemotherapy in the advanced-disease setting.
Table 3. Incidence of TEAEs (‡15% of patients) and selected laboratory abnormalities by cohort type (combined primary and extension
studies)
Idela 1 R (n 5 32) Idela 1 B (n 5 33) Idela 1 BR (n 5 14) Total (n 5 79)
Grade Grade Grade Grade
Any ‡3 Any ‡3 Any ‡3 Any ‡3
AE, n (%) 32 (100) 26 (81) 33 (100) 32 (97) 14 (100) 12 (86) 79 (100) 70 (89)
Pyrexia 12 (37) 0 21 (64) 1 (3) 10 (71) 1 (7) 43 (54) 2 (2)
Nausea 13 (41) 0 13 (39) 0 9 (64) 0 35 (44) 0
Fatigue 12 (37) 1 (3) 16 (48) 2 (6) 6 (43) 0 34 (43) 3 (4)
Rash 8 (25) 2 (6) 13 (39) 2 (6) 9 (64) 3 (21) 30 (38) 7 (9)
Diarrhea/colitis 13 (41) 6 (19) 11 (33) 3 (9) 5 (36) 3 (21) 29 (37) 12 (15)
Cough 11 (34) 0 13 (39) 0 4 (29) 0 28 (35) 0
Insomnia 7 (22) 0 10 (30) 0 1 (7) 0 18 (23) 0
Upper respiratory infection 7 (22) 0 8 (24) 1 (3) 1 (7) 0 16 (20) 1 (1)
Pneumonia 4 (12) 4 (12) 10 (30) 10 (30) 3 (21) 1 (7) 17 (22) 15 (19)
Chills 4 (12) 0 9 (27) 0 1 (7) 0 14 (18) 0
Vomiting 3 (9) 0 6 (18) 1 (3) 5 (36) 0 14 (18) 1 (1)
Constipation 2 (6) 0 7 (21) 1 (3) 3 (21) 0 12 (15) 1 (1)
Headache 7 (22) 0 4 (12) 0 1 (7) 0 12 (15) 0
Chemistry laboratory abnormality, n (%)
ALT, increased 13 (41) 5 (16) 19 (58) 8 (24) 4 (29) 0 36 (46) 13 (16)
AST, increased 18 (56) 4 (13) 19 (58) 5 (15) 4 (29) 0 41 (52) 9 (11)
Alkaline phosphatase, increased 12 (38) 1 (3) 20 (61) 0 3 (21) 0 35 (44) 1 (1)
Bilirubin, increased 7 (22) 0 9 (27) 0 3 (21) 0 19 (24) 0
Creatinine, increased 7 (22) 0 3 (9) 0 3 (21) 0 13 (16) 0
Hematology laboratory abnormality, n (%)
Lymphocytes, decreased 18 (56) 12 (38) 28 (85) 25 (76) 13 (93) 12 (86) 59 (75) 49 (62)
Neutrophils, decreased 14 (44) 11 (34) 21 (64) 15 (46) 9 (64) 6 (43) 44 (56) 32 (41)
Hemoglobin, decreased 6 (19) 2 (6) 24 (73) 5 (15) 7 (50) 1 (7) 37 (47) 8 (10)
Platelets, decreased 8 (25) 1 (3) 19 (58) 4 (12) 6 (43) 1 (7) 33 (42) 6 (8)
TEAEs classified by PT using MedDRA, version 15.1. Patients who experienced multiple events within the same PT were counted once per PT.
PT, preferred term.
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Similar to treatment with idelalisib monotherapy, 13/79 (16%) of patients
had asymptomatic grade $3 transaminase elevations. Incidence in
the prior trials was 25% in the dose-escalation phase 1 trial17 and
13% in the phase 2 trial.18 As in prior trials, these events occurred
early, with a median onset of 6 weeks (range, 4-12 weeks) and were
managed by temporary interruption. Most patients (9/12) were able
to continue idelalisib after rechallenge at a 100 mg twice-daily dose,
with subsequent dose reescalation. Two patients had grade 4
elevations, but both were successfully rechallenged and remain on
the study. The ALT elevations observed with idelalisib do not appear
to be exacerbated or worsened in the combination therapy setting.
The incidence of grade $3 diarrhea/colitis was comparable to a
prior phase 2 monotherapy trial with a similar duration of idelalisib
exposure, where it occurred in 17% of patients.18 Diarrhea/colitis
was initially treated with antimotility agents, antibiotics, and/or study
drug dose interruptions.23 After excluding infectious etiologies,
steroid (prednisolone or budesonide) treatment could be initiated
at the investigator’s discretion. The steroid schedule used was
prednisolone 1 mg/kg or budesonide 9 mg, with a quick taper after
response. Any-grade rash occurred in 38% of patients, with grade
$3 rash in 7 patients (9%), which is a slightly higher incidence
compared with prior idelalisib monotherapy studies.17,18 Bend-
amustine may have contributed to the increased frequency of rash.
Overall, median PFS was 37.1 months, and median DOR was not yet
reached (with probability of continued response at 55% at 3 years).
These results compare favorably with the idelalisib monotherapy trials,
in which the median PFS and DOR were 7.6 and 18.4 months in the
phase 1 trial17 and 11 and 12.5 months in the phase 2 trial.18 The
study was designed to evaluate safety of combinations with idelalisib
and not intended or powered to compare the different treatment arms;
however, the response durations were largely overlapping for the 3
treatment groups and only diverged in the tail of the curves. The
median response durations were 28.6 months for the IR group and
had not yet been reached for the IB and IBR groups. PFS, DOR, and
TTR did not significantly vary at different idelalisib doses or schedules
within each treatment group. The primary combination treatments
were only administered in the first 2 months (IR) or 6months (IB or IBR
combination), and rituximab maintenance was not part of the protocol,
suggesting a role of idelalisib in the suppression of progression. The
response durations appear to be longer than those observed in
idelalisib monotherapy trials,17,18 or with rituximab,3,9 or bendamustine
therapy studies in relapsed/refractory iNHL.24,25
There are no in vitro models for iNHL to test hypotheses about the
mechanism of action of IR, bendamustine, or bendamustine and
rituximab because all cell lines are derived from aggressive NHLs. In
addition, the effects of inhibiting PI3K malignant B cells and their
Table 4. Incidence of SAEs (>1 patient) by cohort type (combined
primary and extension studies)
Idela 1 R
(n 5 32)
Idela 1 B
(n 5 33)
Idela 1 BR
(n 5 14)
Total
(n 5 79)
SAE, n (%) 14 (44) 23 (70) 11 (79) 48 (61)
Pneumonia 3 (9) 9 (27) 1 (7) 13 (16)
Pyrexia 0 7 (21) 4 (29) 11 (14)
Diarrhea/colitis 2 (6) 3 (9) 2 (14) 7 (9)
Febrile neutropenia 0 5 (15) 0 5 (6)
Rash 1 (3) 1 (3) 4 (29) 6 (8)
Renal failure, acute 2 (6) 1 (3) 0 3 (4)
Sepsis 0 4 (12) 1 (7) 5 (6)
Atrial fibrillation 0 0 2 (14) 2 (2.5)
Cardiac arrest 2 (6) 0 0 2 (2.5)
Herpes zoster 1 (3) 1 (3) 0 2 (2.5)
Pneumonitis 0 2 (6) 0 2 (2.5)
Vomiting 0 1 (3) 1 (7) 2 (2.5)
SAEs classified by PT using MedDRA, version 15.1. Patients who experienced multiple
events within the same PT were counted once per PT.
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Figure 1. Response end points: response rate and changes in SPD. (A) ORR (gray) and CR (black) rates in the combined primary and extension studies. (B) Waterfall plot of
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microenvironment on efficacy can only be tested in a clinical trial. The
concept of combining idelalisib and rituximab was further supported
by the full approval for IR for patients with relapsed CLL.20,26
In the context of these efficacy data associated with apparent
acceptable toxicity, randomized phase 3 trials of IR (#NCT01732913)
or bendamustine/rituximab (#NCT01732926) were initiated. Recently,
an important safety signal of increased AE rates, including deaths, was
seen in 6 phase 3 combination trials of idelalisib in patients with CLL/
SLL/iNHL. Infectious issues were likely a contributing factor. These
trials are undergoing detailed analyses by Gilead Sciences, Inc, and
regulators.27,28 Although we cannot draw robust conclusions on
similarities and differences between patient populations across studies
and other factors that may account for different outcomes, 1 obvious
difference between the 6 closed phase 3 trials and our study is the
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number of prior treatments. Patients in the randomized studies
were treatment-naive or had a median of 1 prior regimen, whereas
our study population and the CAL-101-09 study (US Food and
Drug Administration approval of idelalisib in relapsed/refractory
iNHL) had a median of 3 and 4 prior regimens, respectively.
Lymphoma refractoriness, number of prior therapies, and state of
the patients’ immune systems seem to affect relative risks and
benefits of idelalisib combination regimens in specific disease
contexts. Idelalisib administered to CLL patients frontline is
associated with frequent immune-mediated hepatotoxicity. Lampson
et al29 noted that as median age and number of prior therapies
increased, the frequency of immune-mediated AEs with idelalisib
decreased.
Our data provide an important example of phase 1 trial limitations
and the value of conducting phase 3 studies before adopting new
and potentially toxic regimens. Although idelalisib is useful for some
patients with lymphoid malignancies, its role in combination therapies
for relapsed iNHL remains to be determined. Further assessments of
optimal patient selection, modified treatment dosing and schedules,
supportive care, infection prophylaxis, and increased immune and
infectious monitoring are warranted.
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